US OptionsDetailed Quotes
AMGN240726P332500
- 0.05
- -1.50-96.77%
15min DelayClose Jul 26 16:00 ET
1.15High0.04Low
0.86Open1.55Pre Close48 Volume201 Open Interest332.50Strike Price2.28KTurnover66.94%IV0.72%PremiumJul 26, 2024Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0703Delta0.0840Gamma6697.00Leverage Ratio-5.5976Theta0.0000Rho-470.83Eff Leverage0.0032Vega
Amgen Stock Discussion
FDA approves Blincyto® for a specific type of leukemia* in consolidation phase
*CD19-Positive Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (B-All)
» Blincyto® + chemo cuts death risk by 58% in consolidation phase 👏
» superior survival vs. chemo alone
» 1st BiTE® therapy for consolidation, regardless of MRD status
» marks the 3rd indication for BLINCYTO
$GlaxoSmithKline(GSK.US)$ : Arexvy
$Genfit(GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US)$ : Elafibranor
$Eli Lilly and Co(LLY.US)$ : Donanemab - AdCom meeting 🗓️
$Regeneron Pharmaceuticals(REGN.US)$ : Kevzara (sarilumab)
$Bristol-Myers Squibb(BMY.US)$ : Augtyro™ (Repotrectinib)
$Geron(GERN.US)$ : Imetelstat
$Merck & Co(MRK.US)$ : V116
$Amgen(AMGN.US)$ : BLINCYTO (blinatumomab)
$Sarepta Therapeutics(SRPT.US)$ : ELEVIDYS
$Merck & Co(MRK.US)$ : KEYTRUDA ...
$Eli Lilly and Co(LLY.US)$ easily 400+ Billion valuation from Obesity drug
$Novo-Nordisk A/S(NVO.US)$ 50-100 Billion if not wrong
$Amgen(AMGN.US)$ 20+ Billion on no data yet
$Bristol-Myers Squibb(BMY.US)$ : Breyanzi
‣ PDUFA date: 5/31/24 (sBLA)
$Moderna(MRNA.US)$ : mRNA-1345
‣ PDUFA date: End of May 2024 (est.) (BLA)
📣 Buckle up & get ready for next month...
June brings 17 PDUFA decisions: 🔥 🔥
$Catalyst Pharmaceuticals(CPRX.US)$ : FIRDAPSE® (Amifampridine)
$GlaxoSmithKline(GSK.US)$ : Arexvy
$Genfit(GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US)$ : Elafibranor
$Regeneron Pharmaceuticals(REGN.US)$ : Kevzara (sarilumab)
$Bristol-Myers Squibb(BMY.US)$ : Augtyro...
🗓️ Last week’s PDUFAs:
$Amgen(AMGN.US)$ : Approved 5/16 🎉
⇒ Imdelltra (Tarlatamab-dlle)
‣ extensive-stage SCLC
‣ PDUFA date: 6/12/24 (BLA)
$Bristol-Myers Squibb(BMY.US)$ : Approved 5/15 🎉
⇒ Breyanzi®
‣ Follicular lymphoma
‣ PDUFA date: 5/23/24 (sBLAs)
$Dynavax Technologies(DVAX.US)$ : CRL 5/14 🙁
⚠️ insufficient data
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S(ASND.US)$ : Review extended to 8/14/24 🤔
⇒ YORV...
This time around, FOMC nonaction and low jobs numbers helped push equities in the green, or it migh just be because April is finally over. My name is Kevin Travers, here are stories moving the market:
MOOVERS
$Amgen (AMGN.US)$'s stock soared 12% toward biggest gain in 15 years, adding more than 220 points to the...
No comment yet